metricas
covid
Buscar en
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Toda la web
Inicio Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinom...
Journal Information
Vol. 31. Issue 5.
Pages 257-260 (September - October 2012)
Share
Share
Download PDF
More article options
Visits
885
Vol. 31. Issue 5.
Pages 257-260 (September - October 2012)
Original article
The value of FDG-PET/CT in the post-treatment evaluation of endometrial carcinoma: A comparison of PET/CT findings with conventional imaging and CA 125 as a tumour marker
El valor de FDG-PET/TAC en la evaluación post-tratamiento del cáncer de endometrio: Comparación de los hallazgos PET/TAC con imágenes convencionales y CA125 como marcador tumoral
Visits
885
P. Ozcan Karaa,
Corresponding author
ppelinozcan@gmail.com

Corresponding author.
, T. Karab, B. Kayac, G. Kara Gedika, O. Saric
a Selcuk University, Selcuklu Medical Faculty, Department of Nuclear Medicine, Selcuklu, Konya, Turkey
b Beyhekim Hospital, Department of Radiology, Selcuklu, Konya, Turkey
c Selcuk University, Meram Medical Faculty, Department of Nuclear Medicine, Meram, Konya, Turkey
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (4)
Table 1. Clinical characteristics of patients with endometrial carcinoma.
Table 2. The overall study-based results.
Table 3. The overall lesion-based analysis.
Table 4. The overall lesion-based site by site results.
Show moreShow less
Abstract
Objectives

This retrospective study was designed to assess the value of positron emission tomography/computed tomography imaging (PET/CT) in the post-treatment evaluation of the patients with endometrial carcinoma and to compare PET/CT scan with conventional imaging (CI) including computed tomography (CT), ultrasonography (US) and magnetic resonance imaging (MRI) and CA 125 with both 20U/ml and 35U/ml cut-off values.

Materials and methods

A total of 31 patients who were treated for histopathologically proven endometrial adenocarcinoma, underwent PET/CT examination for restaging and suspected recurrence. Thirty five PET/CT studies were performed in 31 patients. Lesion status was determined on the basis of clinical follow-up including radiological imaging (follow-up CT scan) at least 6 months and response to therapy.

Results

Of the 35 PET/CT studies, 13 (37%) studies were positive, whereas 22 (63%) of them were negative. On study-based analysis the overall sensitivity, specificity, accuracy for PET/CT imaging were 100%, 96% and 97%, respectively. The corresponding information for CI were 46%, 87% and 74%, for CA 125 (cut off=20U/ml) measurement were 45%, 88% and 74%, and for CA 125 (cut off=35U/ml) measurement were 27%, 100% and 78%, respectively. On lesion-based analysis, PET/CT revealed only one false positive case. In none of 21 patients with negative 22 PET/CT studies, no subsequent clinical or radiological recurrences were observed with a follow-up of at least 6 months.

Conclusion

FDG-PET/CT is found more useful modality than CI and CA 125 in the evaluation of post-treatment endometrial carcinoma patients, for suspected recurrence.

Keywords:
Endometrial carcinoma
FDG-PET/CT
CA 125
Resumen
Objetivos

Este estudio retrospectivo fue diseñado para evaluar el valor de la tomografía por emisión de positrones/tomografía axial computerizada (PET/TAC) en la evaluación pos-tratamiento de pacientes con cáncer de endometrio y comparar el estudio de PET/TAC con imágenes convencionales (IC), incluyendo la tomografía axial computerizada (TAC), ecografía (echo) y resonancia magnética (RM) y CA 125 con valores de corte de 20U/Ml y 35ml.

Materiales y métodos

Se realizó un estudio de PET/TAC en 31 pacientes tratados por adenocáncer endometrio comprobado histopatologicamente para obtener reestadiaje y en la presencia de sospecha de recaída. Se realizaron 35 estudios de PET/TAC en 31 pacientes. El estado de la lesión fue determinado a partir del seguimiento clínico, incluyendo imágenes radiológicas (seguimiento del estudio de TAC) después de al menos 6 meses y respuesta a tratamiento.

Resultados

Trece (37%) de los 35 estudios PET/TAC fueron positivos y 22 (63%) negativos. El análisis basado en el estudio demostró sensibilidad, especificidad, precisión para las imágenes de PET/TAC de 100%, 96% y 97%, respectivamente. Los datos correspondientes para la IC fueron 46%, 87% y 74% y para CA 125 (punto de corte=20U/ml), las mediciones fueron 27%, 100% y 78%, respectivamente. Basado en el análisis de la lesión, la PET/TAC sólo demostró un caso de falso positivo. No fueron observadas recaídas clínicas o radiológicas con un seguimiento de al menos 6 meses en los 21 pacientes con 22 estudios negativos de PET/TAC.

Conclusiones

La FDG-PET/TAC es una modalidad más útil que la IC y CA 125 en la evaluación post-tratamiento de pacientes con cáncer de endometrio en búsqueda de sospecha de recaída.

Palabras clave:
Cáncer de endometrio
FDG-PET/TAC
CA 125

Article

These are the options to access the full texts of the publication Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos